- Home
- SOR vs CMPS Comparison
SOR vs CMPS Comparison
Compare SOR & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOR
- CMPS
- Stock Information
- Founded
- SOR 1968
- CMPS 2020
- Country
- SOR United States
- CMPS United Kingdom
- Employees
- SOR N/A
- CMPS N/A
- Industry
- SOR Investment Managers
- CMPS Biotechnology: Pharmaceutical Preparations
- Sector
- SOR Finance
- CMPS Health Care
- Exchange
- SOR Nasdaq
- CMPS Nasdaq
- Market Cap
- SOR 358.4M
- CMPS 364.9M
- IPO Year
- SOR N/A
- CMPS 2020
- Fundamental
- Price
- SOR $44.00
- CMPS $4.61
- Analyst Decision
- SOR
- CMPS Strong Buy
- Analyst Count
- SOR 0
- CMPS 7
- Target Price
- SOR N/A
- CMPS $17.00
- AVG Volume (30 Days)
- SOR 16.2K
- CMPS 1.8M
- Earning Date
- SOR 01-01-0001
- CMPS 07-31-2025
- Dividend Yield
- SOR 7.24%
- CMPS N/A
- EPS Growth
- SOR N/A
- CMPS N/A
- EPS
- SOR 6.50
- CMPS N/A
- Revenue
- SOR N/A
- CMPS N/A
- Revenue This Year
- SOR N/A
- CMPS N/A
- Revenue Next Year
- SOR N/A
- CMPS N/A
- P/E Ratio
- SOR $6.41
- CMPS N/A
- Revenue Growth
- SOR N/A
- CMPS N/A
- 52 Week Low
- SOR $36.41
- CMPS $2.25
- 52 Week High
- SOR $42.75
- CMPS $8.54
- Technical
- Relative Strength Index (RSI)
- SOR 56.59
- CMPS 60.45
- Support Level
- SOR $43.65
- CMPS $3.97
- Resistance Level
- SOR $44.80
- CMPS $4.42
- Average True Range (ATR)
- SOR 0.72
- CMPS 0.22
- MACD
- SOR -0.01
- CMPS -0.01
- Stochastic Oscillator
- SOR 47.70
- CMPS 91.43
About SOR Source Capital Inc.
Source Capital Inc is a diversified, closed-end management investment company. The investment objective of the company is to seek maximum total return for Common shareholders from both capital appreciation and investment income to the extent consistent with the protection of invested capital.
About CMPS COMPASS Pathways Plc American Depository Shares
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of major depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.